Washington (Web Desk) — US President Donald Trump has announced a set of reforms aimed at accelerating access to psychiatric treatments, including therapies based on psychedelic substances.
According to a Reuters report, the president has signed an executive order to fast-track medical research and regulatory approvals for emerging treatments targeting mental health conditions.
Trump warns Iran over Strait of Hormuz tensions
Under the new directive, the Food and Drug Administration will expedite the review process for drugs such as Ibogaine, which has been studied for its potential to treat Post-Traumatic Stress Disorder, particularly among military personnel.
US officials say the reforms could pave the way for the reclassification of certain substances that are currently restricted due to their hallucinogenic effects, provided they demonstrate safety and effectiveness in clinical trials.
President Trump also announced a federal allocation of $50 million to support further research into ibogaine, signaling increased government interest in alternative psychiatric treatments.
Comments are closed, but trackbacks and pingbacks are open.